Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 27,898 shares, an increase of 257.5% from the January 15th total of 7,804 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average trading volume of 638,622 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 638,622 shares, the short-interest ratio is presently 0.0 days. Currently, 0.3% of the company’s stock are short sold.

Lisata Therapeutics Trading Up 0.2%

NASDAQ LSTA traded up $0.01 on Thursday, hitting $4.55. 76,977 shares of the company’s stock traded hands, compared to its average volume of 286,451. The firm has a market capitalization of $40.13 million, a PE ratio of -2.14 and a beta of 1.25. Lisata Therapeutics has a 1-year low of $1.81 and a 1-year high of $4.89. The firm’s 50-day moving average price is $2.80 and its two-hundred day moving average price is $2.53.

Analyst Ratings Changes

Several analysts have recently commented on LSTA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Thursday, January 22nd. Brookline Capital Acquisition lowered Lisata Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Finally, Zacks Research downgraded Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.50.

Institutional Investors Weigh In On Lisata Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its position in shares of Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after purchasing an additional 7,093 shares during the last quarter. Ground Swell Capital LLC raised its holdings in shares of Lisata Therapeutics by 64.0% during the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock valued at $73,000 after acquiring an additional 15,213 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of Lisata Therapeutics in the third quarter valued at approximately $37,000. Finally, Cerity Partners LLC acquired a new stake in shares of Lisata Therapeutics in the second quarter worth approximately $32,000. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.